US Edition
News from oncnursingnews.com
We’ve assigned a media bias rating of unknown to oncnursingnews.com. You can read more about our methodology here.
If you want to know if oncnursingnews.com is credible or reliable, look no further. We rank oncnursingnews.com as Unknown factuality. Find out more about our methodology here.
Information about oncnursingnews.com
Where is oncnursingnews.com located?oncnursingnews.com's WebsiteMedia Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top oncnursingnews.com News
Johnson & Johnson · PennsylvaniaThe U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).See the Story
FDA Approves First Subcutaneous Drug for EGFR-Mutated Non-Small Cell Lung Cancer
77% Center coverage: 22 sources
FDA · United States(MedPage Today) -- The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Approval was based on results...See the Story
AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment
80% Center coverage: 10 sources
